Familial disease predisposition impacts treatment outcome in patients with waldenström macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 6, 2012, Pages 433-437

  Treon, Steven P ^a   Tripsas, Christina ^a   Hanzis, Christina ^a   Ioakimidis, Leukothea ^a   Patterson, Christopher J ^a   Manning, Robert J ^a   Sheehy, Patricia ^a   Turnbull, Barry ^b   Hunter, Zachary R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Biobridges Inc   (United States)

Author keywords

Bortezomib; Familial predisposition; Rituximab; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG RESPONSE; FAMILIAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84869472021     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.08.006     Document Type: Article

References (16)

1. N. Chatterjee, P. Hartge, J.R. Cerhan Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers Cancer Epidemiol Biomarkers Prev 13 2004 1415 1421
2. A. Altieri, J.L. Bermejo, K. Hemminki Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish family-cancer database Blood 106 2005 668 672
3. F.R. Mauro, E. Giammartini, M. Gentile Clinical features and outcome of familial chronic lymphocytic leukemia Haematologica 91 2006 1117 1120
4. S.P. Treon, Z.R. Hunter, A. Aggarwal Characterization of familial Waldenstrom's macroglobulinemia Ann Oncol 17 2006 488 494
5. J.R. Brown, D. Neuberg, K. Phillips Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders Br J Haematol 143 2008 361 368
6. L.A. Anderson, R.M. Pfeiffer, J.S. Rapkin Survival patterns among lymphoma patients with a family history of lymphoma J Clin Oncol 26 2008 4958 4965
7. C. Hanzis, R.P. Ojha, Z. Hunter Associated malignancies in patients with Waldenström's macroglobulinemia and their kin Clinical Lymphoma Myeloma Leuk 11 2011 88 92
8. S.P. Treon, J.D. Soumerai, A.R. Branagan Thalidomide and rituximab in Waldenstrom macroglobulinemia Blood 112 2008 4452 4457
9. S.P. Treon, J.D. Soumerai, A.R. Branagan Lenalidomide and rituximab in Waldenstrom's macroglobulinemia Clin Cancer Res 15 2008 355 360
10. L. Ioakimidis, C.J. Patterson, Z.R. Hunter Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia Clin Lymphoma Myeloma 9 2009 62 66
11. S.P. Treon, A.R. Branagan, L. Ioakimidis Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Blood 113 2009 3673 3678
12. S.P. Treon, L. Ioakimidis, J.D. Soumerai Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 J Clin Oncol 27 2009 3830 3835
13. E. Kimby, S.P. Treon, A. Anagnostopoulos Update on recommendations for assessing response from the third International workshop on Waldenstrom's macroglobulinemia Clin Lymphoma Myeloma 6 2006 380 383
14. S.P. Treon, G. Yang, C. Hanzis Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia Br J Haematol 154 2011 223 228
15. Z.H. Hunter, E. Hatjiharissi, J. Sun Gene expression profiling distinguishes Waldenstrom's macroglobulinemia patients presenting with familial disease Advanced IPSS prognostic score, and previous treatment with rituximab Blood 114 2009 1511 abstract 3930
16. P. Morel, A. Duhamel, P. Gobbi International prognostic scoring system for Waldenstrom macroglobulinemia Blood 113 2009 4163 4170